×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALDX – aldeyra therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALDX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/9
11:58 am
aldx
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock? [Yahoo! Finance]
Low
Report
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock? [Yahoo! Finance]
12/2
07:00 am
aldx
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
Low
Report
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
11/19
11:53 am
aldx
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap [Yahoo! Finance]
Medium
Report
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap [Yahoo! Finance]
11/18
07:00 am
aldx
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
Medium
Report
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
11/14
07:00 am
aldx
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
Medium
Report
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
10/31
07:00 am
aldx
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
Low
Report
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
10/3
08:41 am
aldx
Aldeyra Therapeutics resubmits new drug application for treatment of dry eye disease [Seeking Alpha]
Medium
Report
Aldeyra Therapeutics resubmits new drug application for treatment of dry eye disease [Seeking Alpha]
10/3
07:00 am
aldx
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Low
Report
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Date
Time
Symbol
Company Name
Action
%Chg
11/7/2024
04:02 pm
aldx
aldeyra therapeutics, inc.
IN-LINE
Report
5.5%
aldeyra therapeutics, inc.
8/1/2024
04:03 pm
aldx
aldeyra therapeutics, inc.
MISS
Report
-5.3%
aldeyra therapeutics, inc.
5/2/2024
04:03 pm
aldx
aldeyra therapeutics, inc.
MISS
Report
1.7%
aldeyra therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/18
07:01 am
aldx
Form 8-K Aldeyra Therapeutics, For: Nov 15
Medium
Report
Form 8-K Aldeyra Therapeutics, For: Nov 15
11/14
04:51 pm
aldx
Form SC 13G/A Aldeyra Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
Medium
Report
Form SC 13G/A Aldeyra Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
11/7
04:02 pm
aldx
Form 10-Q Aldeyra Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Aldeyra Therapeutics, For: Sep 30
10/21
08:23 pm
aldx
Form 4 Aldeyra Therapeutics, For: May 03 Filed by: Miller-Rich Nancy
Low
Report
Form 4 Aldeyra Therapeutics, For: May 03 Filed by: Miller-Rich Nancy
10/3
07:01 am
aldx
Form 8-K Aldeyra Therapeutics, For: Oct 03
Low
Report
Form 8-K Aldeyra Therapeutics, For: Oct 03
10/2
04:11 pm
aldx
Form 8-K Aldeyra Therapeutics, For: Sep 30
Low
Report
Form 8-K Aldeyra Therapeutics, For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/15
Form 3 Aldeyra Therapeutics, For: Jan 13 Filed by: Miller-Rich Nancy
4.2%
11/1 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update 5.0%
12/18 Form 4 Aldeyra Therapeutics, For: Dec 16 Filed by: Brady Todd C 5.9%
10/2 Form 4 Aldeyra Therapeutics, For: Sep 30 Filed by: Brady Todd C 8.1%
3/26 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.0%
10/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
4/27 Form DEF 14A Aldeyra Therapeutics, For: Jun 09 13.1%
9/9 Form 4 Aldeyra Therapeutics, For: Sep 05 Filed by: McMullin David 13.9%
3/24 Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection 22.9%
4/14 Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629 27.8%
11/1 Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update 5.0%
12/18 Form 4 Aldeyra Therapeutics, For: Dec 16 Filed by: Brady Todd C 5.9%
10/2 Form 4 Aldeyra Therapeutics, For: Sep 30 Filed by: Brady Todd C 8.1%
3/26 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.0%
10/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
4/27 Form DEF 14A Aldeyra Therapeutics, For: Jun 09 13.1%
9/9 Form 4 Aldeyra Therapeutics, For: Sep 05 Filed by: McMullin David 13.9%
3/24 Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection 22.9%
4/14 Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629 27.8%
TOP News Decliners
4/30
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First-Quarter 2020 Financial Results and Corporate Update
-6.0%
10/31 Form 8-K Aldeyra Therapeutics, For: Oct 31 -6.7%
2/25 Form SC 13G Aldeyra Therapeutics, Filed by: Prosight Management, LP -7.0%
2/24 Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day -7.3%
8/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.5%
3/12 Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones -14.2%
3/6 Form 4/A Aldeyra Therapeutics, For: Mar 02 Filed by: Reed Joshua -15.3%
3/17 Form 4 Aldeyra Therapeutics, For: Mar 16 Filed by: DOUGLAS RICHARD -15.3%
3/24 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. -17.8%
12/3 Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease -40.4%
10/31 Form 8-K Aldeyra Therapeutics, For: Oct 31 -6.7%
2/25 Form SC 13G Aldeyra Therapeutics, Filed by: Prosight Management, LP -7.0%
2/24 Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day -7.3%
8/14 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.5%
3/12 Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones -14.2%
3/6 Form 4/A Aldeyra Therapeutics, For: Mar 02 Filed by: Reed Joshua -15.3%
3/17 Form 4 Aldeyra Therapeutics, For: Mar 16 Filed by: DOUGLAS RICHARD -15.3%
3/24 Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. -17.8%
12/3 Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease -40.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: